|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Hepatic venous outflow obstruction:Three similar syndromes显示文摘Our goal is to provide a detailed review of veno- occlusive disease (VOD), Budd-Chiari syndrome (BCS), and congestive hepatopathy (CH), all of which results in hepatic venous outflow obstruction. This is the first article in which all three syndromes have been reviewed, enabling the reader to compare the characteristics of these disorders. The histological findings in VOD, BCS, and CH are almost identical: sinusoidal congestion and cell necrosis mostly in perivenular areas of hepatic acini which eventually leads to bridging fibrosis between adjacent central veins. Tender hepatomegaly with jaundice and ascites is common to all three conditions. However, the clinical presentation depends mostly on the extent and rapidity of the outflow obstruction. Although the etiology and treatment are completely different in VOD, BCS, and CH; the similarities in clinical manifestations and liver histology may suggest a common mechanism of hepatic injury and adaptation in response to increased sinusoidal pressure. | Ulas Darda Bayraktar Soley Seren Yusuf Bayraktar | 2007 | World Journal of Gastroenterology2007，13，13： | 28 |
| 2 | Molecular basis and management of gastrointestinal stromal tumors显示文摘Molecularly targeted agents have dramatically impacted the management of several cancers. Targeting KIT has led to a new treatment paradigm in gastrointestinal stromal tumors (GISTs). KIT is a cell surface receptor with tyrosine kinases that, upon binding of its ligand, stem cell factor, activates various signaling pathways. Imatinib and sunitinib, both tyrosine kinase inhibitors directed to KIT, were approved for firstand secondline treatment of metastatic and unresectable GISTs. In this article, we will review the molecular pathogenesis of GISTs followed by a discussion of imatinib and sunitinib’s role in the treatment of GISTs. Finally, we will introduce novel therapeutic options for imatiniband sunitinib-resistant GISTs. | Ulas D Bayraktar Soley Bayraktar Caio M Rocha-Lima | 2010 | World Journal of Gastroenterology2010，16，22： | 23 |
| 3 | Treatment of iron deficiency anemia associated with gastrointestinal tract diseases显示文摘The gastrointestinal (GI) tract is a common site of bleeding that may lead to iron deficiency anemia (IDA). Treatment of IDA depends on severity and acuity of patients’ signs and symptoms. While red blood cell transfusions may be required in hemodynamically unstable patients, transfusions should be avoided in chronically anemic patients due to their potential side effects and cost. Iron studies need to be performed after episodes of GI bleeding and stores need to be replenished before anemia develops. Oral iron preparations are efficacious but poorly tolerated due to non-absorbed iron-mediated GI side effects. However, oral iron dose may be reduced with no effect on its efficacy while decreasing side effects and patient discontinuation rates. Parenteral iron therapy replenishes iron stores quicker and is better tolerated than oral therapy. Serious hypersensitive reactions are very rare with new intravenous preparations. While data on worsening of inflammatory bowel disease (IBD) activity by oral iron therapy are not conclusive, parenteral iron therapy still seems to be advantageous in the treatment of IDA in patients with IBD, because oral iron may not be sufficient to overcome the chronic blood loss and GI side effects of oral iron which may mimic IBD exacerbation. Finally, we believe the choice of oral vs parenteral iron therapy in patients with IBD should primarily depend on acuity and severity of patients’ signs and symptoms. | Ulas D Bayraktar Soley Bayraktar | 2010 | World Journal of Gastroenterology2010，16，22： | 13 |
| 4 | Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer显示文摘In spite of advances made in the management of the other more common cancers of the gastrointestinal tract,significant progress in the treatment of pancreatic cancer remains elusive.Nearly as many deaths occur from pancreatic cancer as are diagnosed each year reflecting the poor prognosis typically associated with this disease.Until recently,the only treatment with an impact on survival was surgery.In the palliative setting,gemcitabine(Gem) has been a standard treatment for advanced pancreatic cancer since it was shown a decade ago to result in a superior clinical benefit response and survival compared with bolus 5-fluorouracil.Since then,clinical trials have explored the pharmacokinetic modulation of Gem by fixed dose administration and the combination of Gem with other cytotoxic or the biologically'targeted'agents.However,promising trial results in small phaseⅡtrials have not translated into survival improvements in larger phaseⅢrandomized trials in the advanced disease setting.Two trials have recently reported modest survival improvements with the use of combination treatment with Gem and capecitabine(United Kingdom National Cancer Research GEMCAP trial) or erlotinib(National Cancer Institute of CanadaClinical Trials Group PA.3 trial) .This review will focus on the use of systemic therapy for advanced and metastatic pancreatic cancer,summarizing the results of several recent clinical trials and discuss their implications for clinical practice.We will also discuss briefly the second-line chemotherapy options for advanced pancreatic cancer. | Soley Bayraktar Ulas Darda Bayraktar Caio Max Rocha-Lima | 2010 | World Journal of Gastroenterology2010，16，6： | 11 |
| 5 | Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma显示文摘Non-small-cell lung cancer(NSCLC)remains the leading cause of cancer-related death in both men and women in the United States.Platinum-based doublet chemotherapy has been a standard for patients with advanced stage disease.Improvements in overall survival and quality of life have been modest.Improved knowledge of the aberrant molecular signaling pathways found in NSCLC has led to the development of biomarkers with associated targeted therapeutics,thus changing the treatment paradigm for many NSCLC patients.In this review,we present a summary of many of the currently investigated biologic targets in NSCLC,discuss their current clinical trial status,and also discuss the potential for development of other targeted agents. | Soley Bayraktar Caio M Rocha-Lima | 2013 | World Journal of Clinical Oncology2013，4，2： | 8 |
| 6 | Predictive factors for BRCA1 /BRCA2 mutations in women with ductal carcinoma in situ 显示文摘 | Soley B Nisreen E Angelica MG | 2012 | Can- cer2012，118，： | 1 |
| 7 | Shrimp aquaculture : economic perspectives for policy development 显示文摘 | Neiland AE Soley N | 2001 | Marine Policy2001，25，： | 1 |
| 8 | Sperm-stor- age tubules in the vagina of the ostrich (Struthio camelus) 显示文摘 | Bezuidenhout A J Soley J T Groenewald H B | 1995 | On- derstepoort J Vet Res1995，62，3： | 1 |
| 9 | Shrimp aquaculture:economic perspectives for policy development显示文摘 | Soley N Varley J B | 2001 | Mar Policy2001，25，4： | 1 |
| 10 | Ultrastructre of ostrich (Struthio camelus) spermatozoa Ⅰ:Transmisson electron microscopy显示文摘 | Soley J T Roberets D C | 1993 | Ondersteport Jornal of Veterinary Research1993，60，： | 1 |
| 11 | Utrastructure of ostrich(Struthiocamelus) spermatozoa Ⅱ:Scanning electron microscopy显示文摘 | Soley J T Roberets D C | 1994 | Ondersteport Journal of Veterinary Research1994，61，： | 1 |
| 12 | Shrimp aquaculture: economic perspectives for policy development显示文摘 | Arthur E Neiland Neill Soley Joan Baron Varley David J Whitmarsh | 2001 | Marine Policy2001，，4： | 1 |
| 13 | Sperm-storage tubules in the vagina of the ostrich ( Struthio camelus) 显示文摘 | Soley H B Groenewald H B | 1995 | Onderstepoort Journal Veterinary Research1995，62，： | 1 |
| 14 | Prevenar experience 显示文摘 | Arguedas A Soley C Abdelnour A | 2011 | Vaccine2011，29，3： | 1 |
| 15 | Centriole development and formation of the flagellum during spermiogenesis in the ostrich(Struthio-Camelus)显示文摘 | Soley J | 1994 | Journal of Anatomy1994，185，2： | 1 |
| 16 | The antilipolytic effects of insulin and epidermal growth factor in rat adipocytes are mediated by different mechanisms显示文摘 | Tebar F Soley M Ramirez L | 1996 | Endocrinology1996，137，： | 1 |
| 17 | A phase I trial of E7974 administered on day 1 of a 21-day cycle in patients with advanced solid tumors 显示文摘 | Caio M Rocha-Lima Soley Bayraktar Jessica MacIntyre | 2012 | Cancer2012，118，17： | 1 |
| 18 | The etology of effort syndrome显示文摘 | Soley MD Shock NW | 1938 | Am J MedSci1938，196，： | 1 |
| 19 | A multicenter phase II study of G17DT immunogen plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan显示文摘 | Caio Max Rocha-Lima Eriberto Queiroz Marques Junior Soley Bayraktar Paul Broome Charles Weissman Marek Nowacki Martin Leslie Shabbir Susnerwala | 2014 | Cancer Chemotherapy and Pharmacology2014，，3： | 1 |
| 20 | Shrimp aquaculture: economic perspectives for policy development显示文摘 | Neiland A E Soley N Varley J B | 2001 | Marine Policy2001，25，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员